Institut Català de la Salut
[Kervella D, Meneghini M, Torres IB, Castañeda Z, Moreso F, Bestard O] Unitat de Trasplantament Renal, Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Casanova-Ferrer F, Donadeu L, Crespo E, Martínez-Lacalle A] Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Kotton CN] Infectious Diseases Division, Immunocompromised Host Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. [Kumar D] Transplant Infectious Diseases, Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada. [Pineda S] Department of Statistics and Data Science, Complutense University of Madrid, Madrid, Spain. [Martinez-Gallo M] Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Len O, Los-Arcos I] Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Trilla-Herrera E, Miret E] Grup de Recerca de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-10-15T10:06:56Z
2025-10-15T10:06:56Z
2025-09
Breastfeeding; Breast cancer
Lactancia materna; Cáncer de mama
Lactància materna; Càncer de mama
Background: We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods: This was an international, multicentre, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS) and overall survival (OS) were compared between patients who breastfed after delivery and those who did not. Results: Among 4732 patients included from 78 centres worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%).After a median follow up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 37% in the no breastfeeding group (adjusted subdistribution hazard ratio[HR]=1.08, 95%CI 0.57-2.06). No difference in DFS (aHR = 0.83, 95%CI 0.49-1.41) nor in OS (aHR = 1.32, 95%CI 0.31-5.66) was observed. Conclusions: Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety.
LD received a research fellowship grant from the “Instituto de Salud Carlos III” [FI22/00252]. OB’s research activity is partly supported by Instituto de Salud Carlos III (ISCII) (grant numbers PI19/01710 and PI22/01019) (Cofunded by European Regional Development Fund, ERDF-ESF, a way to build Europe) and RICORS (redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III. In addition, the work was partially funded by a European Union’s Horizon 2020 research and innovation program under grant agreement No 754995 (EUTRAIN). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding institutions.
Article
Published version
English
Mama - Càncer - Aspectes genètics; Alletament; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/genetics; PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Behavior::Feeding Behavior::Breast Feeding; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/genética; PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::conducta::conducta alimentaria::lactancia materna
Elsevier
Kidney International Reports;10(9)
https://doi.org/10.1016/j.ekir.2025.06.056
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/FI22%2F00252
info:eu-repo/grantAgreement/EC/H2020/754995
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1665]